With more-advanced renal failure, phosphate binders become necessary to maintain phosphate balance and to prevent hyperphosphatemia. Because of toxicity, aluminum-containing phosphate binders are ...

Nonadherence to phosphate binders is a significant challenge ... the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents ...

rather than aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also be on the decline in the era of aluminium removal from dialysis fluid ...

A change in Medicare coverage for some dialysis medications has left nursing homes and their patients receiving in-house treatment for kidney failure in a serious bind.

(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ... on the limitations of current phosphate binders and their effect on patients ...

Nonadherence to phosphate binders is a significant challenge contributing ... that occurs in nearly all patients with End Stage Renal Disease (ESRD). If left untreated, hyperphosphatemia leads ...

Nonadherence to phosphate binders is a significant challenge ... the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents ...

Unicycive Therapeutics (UNCY) announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum ...

Nonadherence to phosphate binders is a significant challenge contributing to elevated phosphate levels ... Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End ...